Loading...
A Propensity Score Matching Analysis of Dasatinib and Nilotonib as a Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase
BACKGROUND: Both dasatinib and nilotinib are approved frontline therapy for chronic myeloid leukemia, chronic phase (CML-CP) based on randomized trials compared to imatinib. However, no head to head comparison of dasatinib and nilotinib has been conducted in newly diagnosed CML-CP patients. METHOD:...
Na minha lista:
| Udgivet i: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5073019/ https://ncbi.nlm.nih.gov/pubmed/27509035 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30197 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|